Médecine thérapeutique / Pédiatrie
MENUAuto-immune myasthenia in childhood: possible new therapeutic approaches? Volume 17, issue 3, Juillet-Août-Septembre 2014
Authors
Unité de neurologie pédiatrique, Hôpital Necker-Enfants malades, AP-HP, 149, rue de Sèvres, 75015 Paris, France
* Tirés à part
- Key words: myasthenia, treatment, immunosuppression, rituximab
- DOI : 10.1684/mtp.2014.0528
- Page(s) : 197-201
- Published in: 2014
Auto-immune myasthenia is a potentially very severe condition in children, with a high risk of acute decompensation and chronic motor disability. Treatment of the disorder remains complex and requires trained practitioners. Treatment includes anti-cholinesterases, combined with corticosteroids with or without immunosuppressors for modern-to-severe forms A wide range of immunosuppression therapies are used, which significantly improve symptoms. Rituximab is one such potentially positive treatment.